Leukaemia and Lymphoma

Over the past twenty years or so, this course has become a renowned programme for physicians and scientists with an interest in the diagnosis and treatment of haematological cancers.

The international faculty, including ICML key note lecturers, will guide us through the complexity of the biology and the most relevant clinical problems in leukaemia and lymphoma, offering plenary lectures, practice-oriented training through case presentations, workshops in small groups and ample discussion slots.
The format of the residential course will furthermore offer opportunities for informal exchange of ideas, views and experience among the participants and with the faculty.

The close co-operation between the ESO Course Chairmen and the ICML Committee will assure an optimal co-ordination of the topics between the course and the ICML Congress.  A particular feature of the course will be to include topics and presentations that are important in the field but benefit from the smaller format emphasising clinical judgment and individualisation of treatment in contrast to a large and busy conference.

Attendance to the course will be by registration on a first-come/first-served basis. However, to respect the layout and objectives of the course, attendance will be limited to 80 participants.

We are much looking forward to meeting and working with you at the beautiful campus on Monte Verità near Ascona, in the lovely Italian-speaking South of Switzerland.

Yours sincerely,

Martin F. Fey, MD                                          Joseph Connors, MD
Course Chairman                                          Course Chairman

PARTICIPANTS' PROFILE
The programme is designed for postgraduate medical doctors at any stage of clinical career who are interested in haematological oncology. A mix of experienced clinicians or pathologists etc., and oncology/haematology trainees is welcome.
Scientists (PhD) are very welcome too, but they should be advised that the course will emphasise clinical aspects rather than basic biology.

LEARNING OBJECTIVES
After the course, participants should be able to:
 
- Identify the current clinical issues in haematological cancers as well as the   “burning research questions”,
- Discuss the value of pathology and molecular biology in the diagnosis and   prognosis of haematological neoplasms,
- Understand the principles of the molecular and cellular biology of leukaemias   and lymphoma,
- Summarise the most important clinical studies and data on lymphoma and   leukaemia.

ORGANISING SECRETARIAT AND REGISTRATION
European School of Oncology
ESO Bellinzona Office
Ospedale Regionale, CH-6500 Bellinzona, Switzerland
Ph: +41 91 811 8050 - Fax: +41 91 811 8051
Emails: dknupfer@eso.net, lrichetti@eso.net

VENUE
The course will be held at the Centro Congressi Monte Verità (www.monteverita.org) in Ascona (Southern Switzerland) located on a beautiful hill overlooking Ascona and the Lago Maggiore.
The airport of reference is Lugano. The Malpensa Airport will not be served with transfers.

ARRIVAL AND DEPARTURE TRANSFERS
Transfers will be organised at given times for arrivals on Sunday, 12 June and for departures on Tuesday, 14 June as indicated in the tables below.
After having registered to the course, participants will be offered the option to register to the transfers as well.

Arrivals - Sunday, 12 June

Departures - Tuesday, 14 June

INSURANCE
The organisers bear no responsibility for untoward events in connection with, before, during and after the course. Participants are advised to take out their own personal and travel insurance coverage.
 

11th INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA
The ESO course is held in co-operation with the Organising Committee and will precede the
11th ICML (15-18 June 2011, Lugano, Switzerland). The 11-ICML conference will provide the worldwide most important forum for the discussion of all aspects relating to malignant lymphoma.
ICML and the ESO course are two separate events that require registration to one or the other, or both.
For further information please contact cristiana.brentan@lymphcon.ch or visit www.lymphcon.ch

FACULTY
P. Boffetta, Mount Sinai School of Medicine, Department of Medicine, Hematology and Medical Oncology, New York, US
F. Cavalli, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
B.D. Cheson, Georgetown University Hospital, Department of Hematology, Washington, D.C., US
J.M. Connors, University of British Columbia Cancer Agency, Lymphoma Tumor Group, Vancouver, CA
M.F. Fey, Berne University, Inselspital, Department of Medical Oncology, Berne, CH
M. Ghielmini, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
R. Herrmann, University Hospital, Department of Oncology, Basel, CH
C.W. Hess, Berne University, Inselspital, Department of Neurology, Berne, CH
D.K. Hossfeld, Medical University, Dept. of Oncology-Haematology, Hamburg, DE
T.A. Lister, St. Bartholomew's Hospital, Department of Medical Oncology, London, UK
L. Mazzucchelli, Cantonal Institute of Pathology in Southern Switzerland, Locarno, CH
B. Möller, Berne University, Inselspital, Department for Rheumatology & Clin. Immunology, Berne, CH
A. Neubauer, Philipps University, Department of Hematology/Oncology, Marburg, DE
J.R. Passweg, Geneva University Hospital, Department of Hematology, Geneva, CH
S. Stilgenbauer, University of Ulm, Department  of Internal Medicine 3, Haematology and Oncology, Ulm, DE
J.M. Vose, University of Nebraska Medical Centre, Hematology-Oncology Section, Nebraska, US

14 JUNE